Aspira Women’s Health Inc. to Report Fourth Quarter and Full Year 2020 Financial Results
Get Alerts AWH Hot Sheet
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 147.1%
Revenue Growth %: +38.9%
Join SI Premium – FREE
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the fourth quarter and full year ended December 31st, 2020, on Thursday, March 25th, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Thursday, March 25th at 4:30 pm ET | |
Domestic: | 877-407-4018 |
International: | 201-689-8471 |
Conference ID: | 13717832 |
Webcast: | http://public.viavid.com/index.php?id=144003 |
About Aspira Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEXTM and EndoCheckTM. Visit our website for more information at www.aspirawh.com.
Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel: 617-430-7577[email protected]
Source: Aspira Women's Health Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AUTODESK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Autodesk, Inc. and Encourages Investors to Contact the Firm
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIV
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!